In the near future, once these relationships have been confirmed, it could be possible to monitor and evaluate the efficacy of treatments by simply evaluating auditory functions; in fact, the inhibition of NLRP3—mentioned as a potentially key factor to stop neurodegeneration [62]—might reverse SNHL in the early stage and stop its progression in the moderate degree too, so a pure-tone audiometry test associated with distortion product otoacoustic emissions (DPOAEs) might be an easy way to monitor drug efficacy. This evidence concerns the gene NLRP3 and sensorineural hearing loss disorder.